People on the Move
Voyager Therapeutics
Voyager Therapeutics, a gene therapy company which launched in February this year for the development of treatments for central nervous system diseases, has announced Bernard Ravina as VP of clinical development. In addition, Dinah Sah’s interim role as senior VP of neuroscience will become permanent.
Ravina joins the seven week-old company from Biogen Idec, where he was medical director in clinical development. Sah previously worked at Alnylam Pharmaceuticals, where she was VP of research.
Mark Levin, Voyager’s interim CEO, said the new hires would be working on the company’s programmes for Parkinson’s disease, a monogenic form of ALS (motor neurone disease) and Friedreich’s ataxia, among others.
Voyager Therapeutics was launched last month in Massachusetts with funding from life sciences investor Third Rock Ventures. It will explore AAV (adeno-associated virus) gene therapy by investing in vector optimization and engineering and dosing techniques.